Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
0.2155
+0.0050 (2.38%)
NASDAQ · Last Trade: Oct 9th, 12:15 PM EDT
Detailed Quote
Previous Close
0.2105
Open
0.2663
Bid
0.2152
Ask
0.2155
Day's Range
0.2000 - 0.2750
52 Week Range
0.0403 - 0.9400
Volume
180,612,641
Market Cap
330.93M
PE Ratio (TTM)
-1.959
EPS (TTM)
-0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
146,834,585
Chart
About Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer. The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies. Read More
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
